Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Martin

Showing results (291-300 of 361) with videos related to

Pageof 37
Sort By:
Clinical Drug Investigation|November 25, 2021
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaKatja Weisel, Thomas Martin, Amrita Krishnan, et al.
Transfusion|October 14, 2022
Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mappingBtissam Chami, Makoto Okuda, Morvarid Moayeri, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 16, 2023
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 StudyMyo Htut, Binod Dhakal, Adam D Cohen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2021
Sex- and Age-Related Differences in the Distribution of Metastases in Patients With Upper Urinary Tract Urothelial CarcinomaMarina Deuker, Giuseppe Rosiello, Lara Franziska Stolzenbach, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2020
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple MyelomaSarah A Holstein, Vera J Suman, Kouros Owzar, et al.
American Journal of Hematology|May 23, 2022
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysisMeletios A Dimopoulos, Philippe Moreau, Bradley Augustson, et al.
Blood Cancer Journal|November 28, 2024
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studiesPaul G Richardson, Aurore Perrot, Joseph Mikhael, et al.
Clinical Genitourinary Cancer|August 13, 2020
Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment ModalitiesMarina Deuker, Thomas Martin, Franziska Stolzenbach, et al.
Blood Advances|May 21, 2020
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myelomaRafael Alonso, María-Teresa Cedena, Sandy Wong, et al.
Blood Advances|April 4, 2024
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapyGuy Ledergor, Zenghua Fan, Kai Wu, et al.
Pageof 37

Showing results (291-300 of 361) with videos related to

Sort By:
Pageof 37
Clinical Drug Investigation|November 25, 2021
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaKatja Weisel, Thomas Martin, Amrita Krishnan, et al.
Transfusion|October 14, 2022
Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mappingBtissam Chami, Makoto Okuda, Morvarid Moayeri, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 16, 2023
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 StudyMyo Htut, Binod Dhakal, Adam D Cohen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2021
Sex- and Age-Related Differences in the Distribution of Metastases in Patients With Upper Urinary Tract Urothelial CarcinomaMarina Deuker, Giuseppe Rosiello, Lara Franziska Stolzenbach, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2020
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple MyelomaSarah A Holstein, Vera J Suman, Kouros Owzar, et al.
American Journal of Hematology|May 23, 2022
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysisMeletios A Dimopoulos, Philippe Moreau, Bradley Augustson, et al.
Blood Cancer Journal|November 28, 2024
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studiesPaul G Richardson, Aurore Perrot, Joseph Mikhael, et al.
Clinical Genitourinary Cancer|August 13, 2020
Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment ModalitiesMarina Deuker, Thomas Martin, Franziska Stolzenbach, et al.
Blood Advances|May 21, 2020
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myelomaRafael Alonso, María-Teresa Cedena, Sandy Wong, et al.
Blood Advances|April 4, 2024
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapyGuy Ledergor, Zenghua Fan, Kai Wu, et al.
Pageof 37